Citations

Clear

959 citation(s) found for "Service, F J".

A Lighter Approach to Language Access: Virtual Interpreter Utilization in Emergency Medical Services (EMS)
Warrington, Christopher E , Ding, Marissa L

Mayo Clinic

Prehospital Emergency Care | November 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-16

10.1080/10903127.2026.2764155 | PMID 43038405 Get It

Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Zanwar, Saurabh S , Hansen, Doris K , Tan, Carlyn R , Peres, Lauren C , Popat, Rakesh , Afrough, Aimaz , Asoori, Sireesha , Dave, Mrugakshi , Portuguese, Andrew J , Kastritis, Efstathios , Davis, James A , Martinez-Lopez, Joaquin , Sborov, Douglas W , Mihalyova, Jana , Bal, Susan , Janakiram, Murali , Ferreri, Christopher , Biran, Noa , Herr, Megan M. , Grajales-Cruz, Ariel F , Khouri, Jack , Castaneda Puglianini, Omar , Liang, Emily C , Zolotov, Eli , Galarza Fortuna, Gliceida M , Julian, Kelley L , Sannareddy, Aishwarya , Anderson, Larry D , Raza, Shahzad , Dima, Danai , Anwer, Faiz , Kumar, Shaji K , Usmani, Saad , Huang, Chiung-Yu , Mian, Hira , Sidana, Surbhi , Patel, Krina , Lin, Yi , Costa, Luciano J

Mayo Clinic

Journal of Clinical Oncology | November 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-01039 | PMID 43024836 Get It

Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.
Clinician Counseling and Patient Storage and Disposal Practices for Opioids Prescribed for Acute Pain: A Multicenter Prospective Cohort Study
Taherifard, Erfan , Ahadpour, Mitra , Chang, Nancy, Allen, Summer V. , Elie, Marie‐Carmelle , Fillmore, W. Jonathan , Gilbert, Gregg H. , Heckmann, Rebekah, Koussis, Patricia, Lee, Christine, Lipkind, Heather S. , Mallama, Celeste A. , Meyer, Tamra E. , Nuckols, Teryl K. , Ritchie, Jessica , Pacanowski, Michael , Page, David B. , Soukup, Mat, Tamang, Stephen, Torbati, Sam , Wallace, Doug, Walter, Lauren A. , Zhao, Yueqin, Shah, Nilay D. , Ross, Joseph S. , Jeffery, Molly Moore

Mayo Clinic

No container title available | November 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.11.04.26367278 Get It

ABSTRACT BACKGROUND Opioids prescribed for acute pain frequently remain unused, creating opportunities for unintended use, accidental ingestion, or diversion. Little is known about counseling patients receive from prescribers or pharmacists on storage and disposal of opioids. OBJECTIVE To characterize clinician counseling on opioid disposal and patient-reported storage, use, and disposal practices among opioid-naïve patients prescribed opioids for acute pain. DESIGN Multicenter prospective cohort study with participant recruitment between September 2020 and March 2023. PARTICIPANTS Opioid-naïve patients prescribed opioids for acute pain in emergency departments, primary care or urgent care clinics, inpatient settings, and dental practices. MAIN MEASURES Patient-reported receipt of counseling on the importance of opioid disposal and appropriate disposal methods; opioid storage practices; use and disposition of prescribed opioids; disposal methods; and reasons for keeping or disposing of leftover opioids. KEY RESULTS Among 1708 participants, the median age was 38 years (IQR, 28-52); most were recruited from emergency departments (n=915; 53.6%) and primary care or urgent care clinics (n=307; 18.0%). Among 1233 participants who answered the question on counseling about the importance of opioid disposal, 811 (65.8%) reported receiving no counseling. Among 1220 participants who answered the question on counseling about appropriate disposal methods, 832 (68.2%) reported receiving no counseling. Among 812 participants who answered the question about storing opioids in a locked location, 610 (75.1%) reported never doing so. Among 929 participants providing information on opioid leftovers and disposition, 618 (66.5%) did not use all prescribed opioids. Among these 618 participants, 258 (42.8%) kept leftover opioids and 345 (57.2%) disposed of them. Among 256 participants who reported reasons for keeping leftover opioids, 159 (62.1%) wanted medication available for the same condition, 70 (27.3%) wanted medication available for a different condition, and 36 (14.1%) did not know how to properly dispose of the medication. CONCLUSIONS Among opioid-naïve patients prescribed opioids for acute pain, counseling about opioid disposal was uncommon, secure storage was infrequent, and leftover opioids were frequent, with many patients keeping leftover opioids for possible future use. These findings suggest opportunities to improve counseling on opioid storage and disposal and encourage safe disposal of unused opioids after acute pain treatment.
Reply
Rubino, Selene , Cannon, Grant W. , Sauer, Brian C. , Braaten, Tawnie , Sauer, Brian C , Cannon, Grant W

Mayo Clinic

Arthritis Care & Research | September 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acr.80154 | PMID 42695803 Get It

Heterozygous truncating variants in BICC1 are a novel cause of autosomal-dominant tubulointerstitial kidney disease
Eylath, Naomi S, Alyea-Herman, Piper, Meyersiek, Julia, Colombo, Dan A., Rennke, Helmut G. , Guleserian, Ava J, Adams, Victoria W, Bianchi, Giada , Maillard, Arnaud , Bergmann, Carsten , Lecker, Stewart H. , Astley, Megan , Taylor, Abigail, Martin, Lauren M. , Means, Sydney, Weller, Nelson, Kmochová, Tereza , Svojšová, Klára , Pavlovičová, Lea , Yang, Hana , Kmoch, Stanislav, Czarnecki, Peter G. , Bianchi, Giada , Eylath, Naomi, Kidd, Kendrah , Colombo, Dan A., Faguer, Stanislas , Izzi, Claudia , Astley, Megan E , Taylor, Abbigail , Martin, Lauren, Sanchez, Antonio, Hodaňová, Kateřina , Stránecký, Viktor , Hartmannová, Hana , Sikora, Jakub , Harris, Peter C. , Kmoch, Stanislav , Bleyer, Anthony J. , Živná, Martina

Mayo Clinic

No container title available | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.20.26360556 Get It

Introduction: Autosomal-dominant tubulointerstitial kidney disease (ADTKD) is characterized by chronic kidney disease (CKD) with an average age of end-stage renal disease (ESRD) of approximately 45 years, bland urinary sediment, the absence of proteinuria and autosomal dominant inheritance. While several causative genes have been found, there remain families in whom no molecular diagnosis has been identified (ADTKD-NMD). Methods: We identified BICC1 truncating variants in several families with ADTKD-NMD in the Wake Forest Rare Inherited Kidney Disease Registry and then screened families in our database and other referred families for BICC1 truncating variants. We performed segregation analysis and characterized affected individuals for clinical and histopathologic phenotypes. We analyzed oligomer formation of BICC1 mutants with wild-type BICC1-, ANKS3- and ANKS6 proteins through co-immunoprecipitation and Western blotting, and we tested for posttranscriptional regulation of the BICC1 target mRNA, Dand5, in a Luciferase reporter assay. Results: We found 6 heterozygous truncating mutations in BICC1 segregating with the ADTKD phenotype in 8 independent pedigrees worldwide. Affected individuals developed kidney failure in the 6th to 7th decade of life that was characterized pathologically by tubular atrophy and interstitial fibrosis. The truncated gene products localized to cytoplasmic bodies and demonstrated various degrees of self-association or binding to the known interaction partners, ANKS3 and ANKS6. While the wild-type BICC1 gene product acts as a posttranscriptional repressor of target mRNAs, all truncation variants exhibited increased expression of substrate mRNA. Conclusions: Truncating variants in BICC1 are a novel cause of ADTKD, segregating with the disease phenotype and upregulating BICC1 target gene expression through a dominant-negative- or a gain-of-function mode of action.
Efficacy and safety of fenfluramine in Dravet syndrome: The impact of patient clinical characteristics
Nabbout, Rima , Sullivan, Joseph , Auvin, Stéphane , Cross, J. Helen , Devinsky, Orrin , Guerrini, Renzo, Knupp, Kelly G. , Perry, Μ. Scott , Sánchez-Carpintero, Rocı́o , Scheffer, Ingrid E., Morita, Diego, Healy, Patrick, Langlois, Mélanie , Lagae, Lieven , Scheffer, Ingrid E. , Gil-Nagel, Antonio , Knupp, Kelly G , Perry, Michael Scott , Sánchez-Carpintero, Rocío , Schoonjans, An-Sofie , Specchio, Nicola , Strzelczyk, Adam , Wheless, James W , Wirrell, Elaine C , Lothe, Amélie , Lagae, Lieven , Auvin, Stéphane , Devinsky, Orrin , Cross, Helen J , Scheffer, Ingrid E , Gil‐Nagel, António , Guerrini, Renzo , Specchio, Nicola , Wheless, James W. , Wirrell, Elaine , Morita, Diego A. , Langlois, Mélanie

Mayo Clinic

Epilepsia Open | August 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi4.70340 | PMID 42632015 Get It

Abstract Objective To assess the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) stratified by age, number of previously attempted antiseizure medications (ASMs), and SCN1A pathogenic variant status. Methods In this post hoc analysis, data from three randomized controlled trials (RCTs) in patients with DS (2–18 years) were pooled and stratified by age (<4; ≥4 years), number of previous ASMs (1–3; 4–6; ≥7), and SCN1A pathogenic variant status ( SCN1A +; SCN1A −). Stratified groups were assessed and compared with the pooled placebo group (change in monthly convulsive seizure frequency [MCSF], longest convulsive seizure‐free interval, and Clinical Global Impression–Improvement [CGI–I] scale scores rated by parents/caregivers and investigators), and safety (treatment‐emergent adverse events [TEAEs]: frequency, days to onset, and proportion resolved). Results Among 348 patients included in the RCTs, 216 were randomized to fenfluramine (0.7 mg/kg/day, n = 88; 0.4 mg/kg/day [with stiripentol], n = 43; 0.2 mg/kg/day, n = 85) and 132 to placebo. Compared with placebo, fenfluramine treatment (all doses combined) resulted in greater MCSF reductions, greater increases in longest convulsive seizure‐free intervals, and a higher proportion of parents/caregivers and investigators reporting clinically meaningful improvement (“Much Improved”, “Very Much Improved”) on CGI–I scores across all stratified groups. CGI–I scores were consistent across fenfluramine doses in most stratified groups, but patients with the fewest number of previous ASMs had the greatest frequency of clinically meaningful improvement on investigator‐rated CGI–I scores. Safety outcomes were similar across all strata. Most TEAEs resolved by end‐of‐study. Significance Fenfluramine treatment was associated with improved seizure outcomes and global functioning compared with placebo regardless of age, number of previous ASMs, and SCN1A status in patients with DS. Fenfluramine was well‐tolerated; no new safety signals were identified. Further studies with larger sample sizes (including adults) and a priori inferential analyses of stratified groups are warranted. Plain Language Summary Patients with Dravet syndrome struggle with seizures and everyday life. In three studies, patients aged 2–18 years received fenfluramine or placebo (sugar pill). Fenfluramine lowered seizures without many side effects. Researchers combined results from these studies to see how fenfluramine worked in different patient groups based on age, number of previous medications, and a gene called SCN1A . They looked at seizure reduction and whether doctors felt patients had improved. In all groups, fenfluramine worked better than placebo, with similar side effects. Researchers believe fenfluramine helped these patients, but some groups were small, so these results need to be confirmed.
Outcomes of Immune Check Point Inhibitor Use in US Veterans With Pre‐Existing Idiopathic Inflammatory Myopathies: Case Series and Literature Review
Крутько, Д. М. , Rubino, Selene , Kunkel, Gary, Rojas, Jorge, Patel, Shardool, Cannon, Grant W. , Braaten, Tawnie , Krutko, Denis , Walsh, Jessica A , Cannon, Grant W , Sauer, Brian C.

Mayo Clinic

ACR Open Rheumatology | August 10, 2026 | Volume: 8 | Issue: 8 | Pages: No page available

10.1002/acr2.90127 | PMID 42572441 Get It

Objective Our objective was to identify and describe the clinical characteristics and outcomes in patients with pre‐existing idiopathic inflammatory myopathies (IIMs) in the Veterans Health Administration (VHA) treated with immune checkpoint inhibitors (ICIs). Methods All veterans receiving ICI infusions were identified. Patients with at least two International Classification of Disease codes for IIM before first ICI infusion underwent chart review to identify patients with confirmed IIM by American College of Rheumatology/EULAR criteria. The demographics, cancer diagnoses, laboratory findings, clinical course, and mortality rates were reported. IIM cases were also reviewed to determine if patients developed IIM flare following ICI treatment. Results We identified 29,539 veterans who received at least one ICI infusion in the VHA between June 6, 2011, and February 14, 2023. The eight patients with confirmed IIM before ICI treatment were mostly White men with an average age of 71.7 years at first ICI infusion. The IIM diagnoses were dermatomyositis in three patients, polymyositis in two, antisynthetase syndrome in two, and one rheumatoid arthritis (RA)/myositis overlap. Cancer diagnoses were lung (two), melanoma (two), head and neck (two), kidney/other urinary (one), and mesothelioma (one). Diagnosis of IIM was made on average 3.1 years before ICI treatment. One patient had an IIM flare after ICI. No IIM flares were identified in other patients. Conclusion Our findings show that an IIM flare after ICI therapy can occur, but most patients did not develop a flare. These observations suggest ICIs can be considered as an option in patients with cancer with IIM with shared decision‐making and close monitoring.
Telemedicine Critical Care Billing For Hospitalized Medicare Fee-For-Service Beneficiaries, 2018–2024
Graves, Jonah M., Waken, R. J., Drewry, Anne M., Subramanian, Sanjay , Scott, Benjamin, Udeh, Chiedozie, Herasevich, Vitaly, Maddox, Karen E. Joynt , Joynt Maddox, Karen E , Ofoma, Uchenna R. , Graves, Jonah M. , Waken, R. J. , Drewry, Anne M. , Udeh, Chiedozie Ifeanyi , Herasevich, Vitaly

Mayo Clinic

Critical Care Medicine | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/ccm.0000000000007301 | PMID 42565664 Get It

Objectives: Expanded coverage for telehealth during the COVID-19 pandemic allowed providers to bill for telemedicine services that were previously not reimbursable, including telemedicine critical care (TCC) services for critically ill patients. We aimed to characterize TCC billing practices among Medicare beneficiaries before, during, and after the COVID-19 pandemic. Design, Setting, and Patients: This was a serial cross-sectional study of adult Medicare Fee-For-Service beneficiaries with at least one bill for critical care at acute care hospitals from January 2018 to September 2024. TCC billing was identified using provider billing codes; multivariate regression models were used to determine characteristics associated with receipt of TCC. Key outcomes were patient-, provider-, and hospital-level characteristics associated with TCC billing. Interventions: None. Measurements and Main Results: Billing for TCC increased from 0.002% of critical care bills pre-pandemic to 0.01% of critical care bills during and after the pandemic. Patients billed for TCC were disproportionately likely to have COVID-19 but were otherwise relatively similar to critically ill patients not billed for TCC. Internal medicine/critical care providers accounted for the highest proportion of pandemic TCC bills (46.0%). TCC billing occurred more often at minor teaching hospitals (adjusted odds ratio [aOR], 1.21; 95% CI, 1.03–1.43) and at safety-net hospitals (aOR, 1.33; 95% CI, 1.04–1.70). TCC billing was less likely at small-sized hospitals (aOR, 0.39; 95% CI 0.26–0.58) and medium-sized hospitals (aOR, 0.67; 95% CI, 0.47–0.95), government-owned hospitals (aOR, 0.70; 95% CI, 0.57–0.86), for-profit hospitals (aOR, 0.58; 95% CI, 0.48–0.71), rural hospitals (aOR, 0.70; 95% CI, 0.55–0.89), and critical access hospitals (aOR, 0.59; 95% CI, 0.47–0.73). Conclusions: Billing for TCC among hospitalized critically ill Medicare beneficiaries increased during the pandemic but remained low as a proportion of all critical care bills. There was variability in utilization across subspecialties and lesser utilization at rural and critical access hospitals. Further studies are needed to characterize the clinical and economic consequences of this shift.
Pyoderma Gangrenosum Phenotype Classification
Gaurav, Ahana , Gregoire, Samantha, Xia, Eric, McIntosh, Basil Alex, Alavi, Afsaneh, Bolognia, Jean, Cowen, Edward, Dominguez, Arturo R., Fivenson, David, Heffernan, Michael, Huang, William, Madigan, Lauren, Mauskar, Melissa, Nelson, Caroline, Patsatsi, Aikaterini , Pugliese, Douglas, Rojek, Nathan W. , Rosenbach, M., Shaigany, Sheila, Shinkai, Kanade , Smith, Gideon, SWERLICK, ROBERT, Ortega-Loayza, Alex, Gregoire, Samantha , Xia, Eric , Fernandez, Anthony P , Fivenson, David , Kaffenberger, B , Madigan, Lauren M. , Mauskar, Melissa , Means, Alexander D. , Pugliese, Douglas J., Rosenbach, Misha , Shaigany, Sheila , Smith, Gideon Piers , Swerlick, Robert A. , Ortega‐Loayza, Alex G. , Mostaghimi, Arash

Mayo Clinic

JAMA Dermatology | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamadermatol.2026.2285 | PMID 42555014 Get It

Importance Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by sterile ulcerative skin lesions. Multiple comorbidities and clinical features have been associated with PG, but no standardized guidelines exist for classifying PG phenotypes. Objective To develop an expert-established classification framework for PG phenotypes to inform treatment guidelines and future research endeavors. Evidence Review In this modified Delphi consensus study that included 23 board-certified dermatologists and Medical Dermatology Society members with expertise in PG, panelists completed 5 rounds of anonymous, iterative online surveys that were administered from December 2023 through July 2025. Before the beginning of the consensus exercise, a literature review was performed by nonvoting researchers to summarize existing data on PG clinical associations and comorbidities. A PubMed search from inception to September 2023 identified observational studies, narrative reviews, systematic reviews, and meta-analyses describing PG clinical associations and comorbidities that were published in English. Experts indicated their agreement with proposed PG phenotypes and disease modifiers with a consensus threshold of 70% or greater. Anonymous comments and aggregated results were presented in each subsequent round. In the final round, a framework of PG phenotypes and disease modifiers was proposed for agreement. Findings Twenty-three board-certified dermatologists and Medical Dermatology Society members with expertise in PG completed 5 rounds of iterative surveys. Consensus was reached on the final set of PG phenotypes and disease modifiers, with 83% of experts in agreement. PG phenotypes were overall classified into 2 major groups: PG with autoinflammatory syndromes and nonsyndromic PG. Nonsyndromic PG included 4 phenotypes: inflammatory bowel disease–associated PG, PG in association with hematologic cancers and blood dyscrasias, drug-induced PG, and other (including idiopathic) PG. Disease modifiers of PG phenotype presentations included involvement of special sites (head/neck, genitals, or peristomal skin) and extracutaneous manifestations. Conclusions and Relevance This expert-established, descriptive framework provides a standardized classification system for distinct PG phenotypes and its modifiers. This nomenclature may inform upcoming clinical guidelines and allow for consistency in reporting epidemiological research and outcomes among patients with PG.
Mental Health Service Use After Randomized Control Trial Comparing Parent-Coached Exposure Therapy and Cognitive Behavioral Therapy for Pediatric Anxiety Disorders: A Chart Review
Gloe, Lilianne M. , Pejic, Jelena , Nix, Jalen, Lipinski, Alexander W. , Knapp, Justin, Nelson, Jessie A., Dammann, Julie E., Auringer, Sara, Wilde, Zachary C. , Whiteside, Stephen P. H. , Biggs, Bridget K.

Mayo Clinic

Child & Family Behavior Therapy | July 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-17

10.1080/07317107.2026.2708640 Get It